Document |
Document Title |
WO/2024/077085A1 |
The present disclosure describes methods of treating a condition comprising administering a compound that inhibits PLA2G7. The present disclosure describes methods of treating a condition comprising administering a compound that inhibits...
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
WO/2024/074577A1 |
The present disclosure relates to methods of preparing a compound of Formula (IX): (IX); or a pharmaceutically acceptable salt thereof. The present disclosure also relates to compounds being prepared by the methods, the pharmaceutical co...
|
WO/2024/074538A1 |
The present disclosure relates to morphic forms of Compound A. The present disclosure also relates to processes for the preparation of the morphic forms of Compound A, the pharmaceutical compositions comprising the morphic forms, and the...
|
WO/2023/196714A3 |
Provided herein are compounds, such as compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs there...
|
WO/2024/067626A1 |
A composite, comprising: 3-hydroxybutyric acid; and one or more of potassium 3-hydroxybutyrate, or calcium 3-hydroxybutyrate, or magnesium 3-hydroxybutyrate. A composite, wherein the anion comprises 3-hydroxyvaleric acid, and the cation ...
|
WO/2024/069507A1 |
This invention relates to novel processes for synthesizing N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphe
nyl)-4-cyclopropyl-2-fluorobenzamide and to intermediates which are used in such processes.
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
WO/2024/073502A1 |
The present disclosure relates to novel compounds that inhibit glucose-induced degradation-deficient (GID) E3 ligase, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related ...
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
WO/2024/064091A1 |
This present invention relates to compounds of Formula I that feature the inhibition of protein tyrosine kinases (PTKs), including EGFR mutants, their pharmaceutical compositions that comprising a therapeutically effective amount of the ...
|
WO/2024/064024A1 |
The present invention relates to ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives of formula (I) as well as to said compounds for use as P13K inhibitors in methods of treatment of cancer.
|
WO/2024/064214A2 |
The present disclosure provides methods of preparing substituted cyclopropane compounds.
|
WO/2024/062479A1 |
The present disclosure relates to a process for the preparation of a brominated uracil derivative of Formula I, wherein R1, R2 and R3 are independently selected from H, and branched or unbranched alkyl group having C1-C7, said process co...
|
WO/2024/061365A1 |
Provided are a compound represented by formula (I), or a tautomer, a cis-trans isomer, a mesomer, a racemate, an enantiomer, a diastereomer, or an atropisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt, a s...
|
WO/2024/058311A1 |
The present invention relates to a method for producing ectoine, the method being charcteriezed by comprising: a step for producing (2-nosyl)-L-glutamine by introducing a nosyl group into L-glutamine as a protecting group; a step for pro...
|
WO/2024/057001A1 |
The present invention relates to compounds of Formula (I) that may act as agonists of retinoic acid receptor alpha (RAR-α) and/or retinoic acid receptor beta (RAR-β). The invention also relates to pharmaceutical compositions comprising...
|
WO/2024/059010A1 |
The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
|
WO/2024/059668A2 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that inhibit epidermal growth factor receptor (EGFR), the methods of maki...
|
WO/2024/050825A1 |
A substituted cyclic compound as represented by formula (I) and having a selective inhibitory effect on MLKL, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing ...
|
WO/2024/054997A1 |
Provided herein are methods to treat rhegmatogenous retinal detachment (RRD) and/or improve visual outcomes of RRD.
|
WO/2024/050366A1 |
Described herein are methods, devices, and systems for identifying a subset of a plurality of features, using one or more feature importance metrics, for training and using a homologous repair deficiency (HRD) classification model. Furth...
|
WO/2024/047648A1 |
The present invention relates to a novel nitration process of 2- chloro-4- fluorobenzoic acid or alkyl 2-chloro-4- fluorobenzoate, using oleum and nitric acid, to obtain 2-chloro-4- fluoro-5- nitrobenzoic acid or alkyl 2-chloro-4-f luoro...
|
WO/2024/045747A1 |
The present application belongs to the technical field of organic materials, and provides an organic compound, an electronic component and an electronic device. The structure of the organic compound is as shown in formula (1), and there ...
|
WO/2024/040497A1 |
An antiviral compound, a preparation method therefor and an use thereof; specifically an anti-coronavirus compound that can be used as a PLPro inhibitor, a preparation method therefor and a use thereof. The compound has a structure repre...
|
WO/2024/044757A1 |
The present disclosure provides compounds and compositions that are useful as MYC protein modulators and methods of using the same for treating MYC-mediated diseases or disorders.
|
WO/2024/037485A1 |
The present invention relates to a preparation method for an amorphous form of the compound of formula I. Specifically, the present invention provides a preparation method for an amorphous form of letermovir, the compound of formula I. T...
|
WO/2023/205618A9 |
Compounds are provided having formula (I) wherein the groups/letters R1a, R1b, m, R2, R3, R4, X, Y, A, B, n, q, L and Q, have the meanings provided herein. The compounds are useful as CCR4 antagonists and are useful in treated diseases a...
|
WO/2024/037520A1 |
Disclosed in the present invention are a new compound as represented by general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer and a racemate thereof, and a pharmaceutical composition containing the compo...
|
WO/2024/037668A1 |
Disclosed are a 2-nitrogen-substituted pyrimidine compound represented by formula I, a respective optical isomer, a deuterated substance, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising th...
|
WO/2024/032597A1 |
A compound having a STING inhibitory effect or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for treating diseases related to abnormal STING expression. Specifically disclosed are compounds of...
|
WO/2024/035688A1 |
Described are the compounds, compositions and methods of treating diseases and disorders that involve aberrant B-cell lymphoma 6 (BCL6) activity.
|
WO/2024/031242A1 |
A method for synthesizing an aryl benzyl thioether compound using photocatalysis. By using the iron (III) complex [HIMXy Me][FeBr 4]([HIMXy Me]=l,3-bis(4-methoxy-2,6-dimethylphenyl)-4,5-dimethylimidaz
olium cation) as a catalyst, fac-Ir(...
|
WO/2024/035921A1 |
This disclosure relates to compounds which are degraders of son of sevenless homolog 1 (SOS1) and their use in treating cancers, in particular KRAS-mutant cancers.
|
WO/2024/027767A1 |
The present invention relates to a herbicide composition comprising a uracil compound comprising at least one carboxylate fragment represented by formula (I) and at least one herbicide active compound, and a use of the herbicide composit...
|
WO/2024/030429A1 |
Various novel nucleoside analogs described herein have the promise of achieving higher efficiency against a variety of viral infections, including the dangerous respiratory ones, like SARS-CoV-2 and COVID-19, as well as lower incidence a...
|
WO/2024/027814A1 |
Disclosed are a compound as represented by formula (I) having a KRas G12D inhibitory effect, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the use thereof in the preparation of a drug for KRas G12D-related...
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
WO/2024/027765A1 |
The present invention relates to the field of pesticides and herbicides, in particular to a method for preparing compound 2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoromethyl)-
3,6-dihydropyrimidin-1(2H)-yl)benzoate of formula (I)....
|
WO/2024/025991A1 |
A method is disclosed of detecting a disease associated with pulmonary vascular remodeling in a subject. The method can comprise administering to the subject a compound of Formula I or Formula II. The method can further comprise imaging ...
|
WO/2024/022998A1 |
The present invention provides crystal forms of daprodustat, which are cocrystals comprising daprodustat free acid and a daprodustat pharmaceutically acceptable metal salt, wherein the metal salt is an alkali metal salt. The invention al...
|
WO/2024/026424A1 |
The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usefu...
|
WO/2024/020170A1 |
Provided herein are compounds which can act agonists of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating inflammatory and autoimmune diseases and disorders, such as diseases or disorders of the gastr...
|
WO/2024/018394A1 |
The present invention relates to a process for the preparation of crystalline form A of N, N'-bis(2-aminoethyl)-1,2-ethanediamine tetrahydrochloride (I).
|
WO/2024/017251A1 |
The present disclosure relates to a macrocycle for inhibiting and inducing EGFR degradation and a preparation method for and a use of the macrocycle. Specifically, the present disclosure relates to a macrocycle as shown in general formul...
|
WO/2024/017258A1 |
Disclosed in the present invention are a multi-target small molecule inhibitor, a pharmaceutical composition containing same, and a use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I)....
|
WO/2024/011414A1 |
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
|
WO/2024/014303A1 |
Provided is a compound represented by formula (1).
|
WO/2024/012554A1 |
The present disclosure belongs to the field of biomedicine, and specifically relates to a method for preventing or treating neurodegenerative diseases or alleviating symptoms of neurodegenerative diseases. Said method comprises administe...
|